Shares of GH Research PLC (NASDAQ:GHRS) surged 90% following the announcement that its Phase 2b trial for GH001, an inhalable treatment for treatment-resistant depression (TRD), met its primary ...
DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
GH001 led to a significant reduction from baseline of -15.2 points in Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 8, compared with +0.3 points in the placebo group (difference ...
The demand for a separate electoral roll for non-tribals in the GHADC by a minority body called Sarvadaliya Sammelan has been rubbished as legally untenable. Social activist from Tura, Cherian Momin ...
THE Board Chairman of the African Union Arts Festival Foundation and Apagyahen of Asebu Traditional Area, Nana Obokese Ampah I, has called on President John Dramani Mahama to prioritise continuity and ...